drugset
Drugs / URLC10
last change Mar 2019 re-read 2 minutes ago

URLC10

also known as LY6K

Peptide

Developed for
non-small cell lung carcinoma · esophageal cancer · gastric cancer · breast cancer
Investigated by
Human Genome Center, Institute of Medical Science, University of Tokyo · Tokyo University · Shiga University · Fukushima Medical University · Kinki University · Saint Luca International Hospital
+3 more · Teikyo University · Tokyo Medical University · University of Yamanashi

Trials 14 · a red edge is where a trial was stopped

today NCT01950156 · Ph 1/2 NCT01949701 · Ph 1/2 NCT01267578 · Ph 2 NCT01069575 · Ph 1 NCT01069640 · Ph 1 NCT01259505 · Ph 1 NCT00874588 · Ph 1 NCT00681330 · Ph 1/2 NCT00681577 · Ph 1/2 NCT00681421 · Ph 1/2 NCT00681252 · Ph 1/2 NCT00632333 · Ph 1 NCT00633724 · Ph 1 NCT00753844 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT01069575 Feb 2010 → Mar 2019 non-small cell lung carcinoma Shiga University Completed No outcome recorded
Phase 1 NCT01069640 Feb 2010 → Mar 2019 non-small cell lung carcinoma Shiga University Completed No outcome recorded
Phase 1 NCT01259505 Dec 2009 → Jun 2012 breast cancer Tokyo Medical University Completed No outcome recorded
Phase 1 NCT00874588 Mar 2009 → Jun 2012 non-small cell lung carcinoma Fukushima Medical University Completed No outcome recorded
Phase 1 NCT00632333 Feb 2008 → Dec 2011 esophageal cancer Teikyo University Unknown No outcome recorded
Phase 1 NCT00633724 May 2007 → Jun 2012 non-small cell lung carcinoma Fukushima Medical University Completed No outcome recorded
Phase 1 NCT00753844 Nov 2006 → Jun 2009 esophageal cancer Kinki University Completed No outcome recorded
Phase 1/26 trials
Phase 1/2 NCT01950156 Sep 2011 → Mar 2019 non-small cell lung carcinoma Shiga University Completed No outcome recorded
Phase 1/2 NCT01949701 Aug 2011 → Mar 2019 non-small cell lung carcinoma Shiga University Completed No outcome recorded
Phase 1/2 NCT00681330 May 2008 → Apr 2009 esophageal cancer Tokyo University Completed No outcome recorded
Phase 1/2 NCT00681577 May 2008 → Oct 2009 gastric cancer Tokyo University Completed No outcome recorded
Phase 1/2 NCT00681421 May 2008 → Apr 2009 esophageal cancer Tokyo University Completed No outcome recorded
Phase 1/2 NCT00681252 May 2008 → Apr 2009 gastric cancer Tokyo University Completed No outcome recorded
Phase 21 trial
Phase 2 NCT01267578 Apr 2010 → May 2011 esophageal cancer University of Yamanashi Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as URLC10 “On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg) and TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.” NCT00681330 ↗
13

“Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides” NCT01267578 ↗

NCT01069640 ↗

NCT00681577 ↗

NCT00681421 ↗

NCT00633724 ↗

NCT00753844 ↗

NCT01069575 ↗

NCT00632333 ↗

NCT01259505 ↗

NCT00874588 ↗

NCT00681252 ↗

NCT01949701 ↗

NCT01950156 ↗
Known as LY6K “The third was a peptide derived from up-regulated lung cancer 10 (URLC10, which is also called lymphocyte antigen 6 complex locus K [LY6K]).” PMID 23578144 ↗ Apr 2013
Modality Peptide “the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51” NCT00681252 ↗
Route Subcutaneous “the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection” NCT00681252 ↗